Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -16.57%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth, gross margin expansion, and positive adjusted net income. However, the company continues to face net losses and increased operating expenses. The introduction of new product features and FDA approvals positions the company well for future growth.Company Guidance
During the fourth quarter of 2024 earnings call, RxSight, Inc. provided guidance for 2025, projecting full-year revenue to range between $185 million and $197 million, representing a year-over-year growth of 32% to 41%. The company expects its gross margin to be between 71% and 73%, reflecting an increase in revenue mix from higher-margin Light Adjustable Lens (LAL) procedures. Operating expenses are anticipated to rise by 22% to 25%, ranging from $165 million to $170 million, with significant investments in sales, marketing, and research and development, including stock-based compensation expenses of $22 million to $25 million. RxSight, Inc. aims to expand its presence in the premium cataract market, with continued growth driven by increased adoption of its adjustable intraocular lens technology and new advancements in its product offerings.Record Growth in Revenue and Sales
Fourth quarter 2024 revenue was $40.2 million, up 41% year-over-year. Full-year 2024 revenue grew by 57% to $139.9 million. A record 29,069 LALs were sold in Q4 2024, up 61% from Q4 2023.
Strong Gross Margin Expansion
Gross margin for Q4 2024 expanded to 71.6%, compared to 61.8% in Q4 2023. Full-year gross profit margin increased to 70.7% from 60.4% in 2023.
Significant Increase in Installed Base
Ended 2024 with an LDD installed base of 971 units, up 46% compared to 666 units at the end of 2023.
Successful Stock Raise
Raised $107.5 million net of fees and expenses from a confidentially marketed public offering, ending 2024 with $237.2 million in cash, cash equivalents, and short-term investments.
Positive Adjusted Net Income
Adjusted net income for Q4 2024 was $1.3 million or $0.03 per basic and diluted share.
FDA Approvals and New Product Features
Received FDA approval for an additional LDD functionality that allows customization of asphericity of LAL, scheduled for release in the second half of 2025.
---
RXST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RXST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $29.21 | $28.97 | -0.82% |
| Nov 07, 2024 | $50.85 | $48.01 | -5.59% |
| Aug 05, 2024 | $40.78 | $47.85 | +17.34% |
| May 06, 2024 | $62.84 | $62.19 | -1.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does RxSight (RXST) report earnings?
RxSight (RXST) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is RxSight (RXST) earnings time?
RxSight (RXST) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXST EPS forecast?
RXST EPS forecast for the fiscal quarter 2025 (Q1) is -0.2.
---